Aftovaxpur DOE

Pays: Union européenne

Langue: anglais

Source: EMA (European Medicines Agency)

Achète-le

Ingrédients actifs:

Maximum three of the following purified, inactivated foot-and-mouth disease virus strains: O1 Manisa ≥ 6 PD50*; O1 BFS ≥ 6 PD50*; O Taiwan 3/97 ≥ 6 PD50*; A22 Iraq ≥ 6 PD50*; A24 Cruzeiro ≥ 6 PD50*; A Turkey 14/98 ≥ 6 PD50*; Asia 1 Shamir ≥ 6 PD50*; SAT2 Saudi Arabia ≥ 6 PD50*; * PD50 – 50% protective dose in cattle as described in Ph. Eur. monograph 0063.

Disponible depuis:

Boehringer Ingelheim Vetmedica GmbH

Code ATC:

QI02AA04

DCI (Dénomination commune internationale):

inactivated vaccine against foot-and-mouth disease

Groupe thérapeutique:

Pigs; Cattle; Sheep

Domaine thérapeutique:

Immunologicals

indications thérapeutiques:

Active immunisation of cattle, sheep and pigs from 2 weeks of age against foot-and-mouth disease to reduce clinical signs.

Descriptif du produit:

Revision: 8

Statut de autorisation:

Withdrawn

Date de l'autorisation:

2013-07-15

Notice patient

                                17
B. PACKAGE LEAFLET
Medicinal product no longer authorised
18
PACKAGE LEAFLET:
AFTOVAXPUR DOE EMULSION FOR INJECTION FOR CATTLE, SHEEP AND PIGS
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
RELEASE, IF DIFFERENT
Marketing authorisation holder:
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
GERMANY
Manufacturer responsible for batch release:
Boehringer Ingelheim Animal Health France SCS
Laboratoire Porte des Alpes
Rue de l’Aviation
69800 Saint Priest
FRANCE
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
AFTOVAXPUR DOE emulsion for injection for cattle, sheep and pigs
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT
Each dose of 2 ml of emulsion contains:
ACTIVE SUBSTANCES:
Purified, inactivated foot-and-mouth disease virus strain antigens, at
least 6 PD
50
* per strain.
* PD
50
– 50% protective dose in cattle as described in Ph. Eur. monograph
0063.
The number and type of strains included in the final product will be
adapted to the current
epidemiological situation at the time of formulation of the final
product and will be shown on the
label.
ADJUVANT:
Liquid paraffin 537 mg.
White emulsion after shaking.
4.
INDICATIONS
Active immunisation of cattle, sheep and pigs from 2 weeks of age
against foot-and-mouth disease to
reduce clinical signs.
Onset of immunity:
Cattle and sheep: 7 days after vaccination.
Pigs: 4 weeks after vaccination.
Medicinal product no longer authorised
19
Duration of immunity: vaccination of cattle, sheep and pigs induced
the production of neutralising
antibodies that persisted for at least 6 months. In cattle, the
antibody levels measured were above
those shown to be protective.
5.
CONTRAINDICATIONS
None.
6.
ADVERSE REACTIONS
Swellings (diameter of up to 12 cm in ruminants and 4 cm in pigs)
occurred very commonly in most
animals after administration of a dose of vaccine. These local
reactions normally resolve over a period
of four weeks post vaccination, but may persist for longer in a s
                                
                                Lire le document complet
                                
                            

Résumé des caractéristiques du produit

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
AFTOVAXPUR DOE emulsion for injection for cattle, sheep and pigs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose of 2 ml of emulsion contains:
ACTIVE SUBSTANCES:
Maximum three of the following purified, inactivated foot-and-mouth
disease virus strains:
O1 Manisa
.................................................................................................................................
≥ 6 PD
50
*
O1 BFS
.......................................................................................................................................
≥ 6 PD
50
*
O Taiwan 3/97
...........................................................................................................................
≥ 6 PD
50
*
A22 Iraq
.....................................................................................................................................
≥ 6 PD
50
*
A24 Cruzeiro
.............................................................................................................................
≥ 6 PD
50
*
A Turkey 14/98
.........................................................................................................................
≥ 6 PD
50
*
Asia 1 Shamir
.............................................................................................................................
≥ 6 PD
50
*
SAT2 Saudi Arabia
...................................................................................................................
≥ 6 PD
50
*
* PD
50
– 50% protective dose in cattle as described in Ph. Eur. monograph
0063.
The number and type of strains included in the final product will be
adapted to the current
epidemiological situation at the time of formulation of the final
product and will be shown on the
label.
ADJUVANT:
Liquid paraffin
.............................................................................................................................

                                
                                Lire le document complet
                                
                            

Documents dans d'autres langues

Notice patient Notice patient bulgare 04-07-2023
Rapport public d'évaluation Rapport public d'évaluation bulgare 13-06-2016
Notice patient Notice patient espagnol 04-07-2023
Rapport public d'évaluation Rapport public d'évaluation espagnol 04-07-2023
Notice patient Notice patient tchèque 04-07-2023
Rapport public d'évaluation Rapport public d'évaluation tchèque 13-06-2016
Notice patient Notice patient danois 04-07-2023
Rapport public d'évaluation Rapport public d'évaluation danois 13-06-2016
Notice patient Notice patient allemand 04-07-2023
Rapport public d'évaluation Rapport public d'évaluation allemand 13-06-2016
Notice patient Notice patient estonien 04-07-2023
Rapport public d'évaluation Rapport public d'évaluation estonien 04-07-2023
Notice patient Notice patient grec 04-07-2023
Notice patient Notice patient français 04-07-2023
Rapport public d'évaluation Rapport public d'évaluation français 04-07-2023
Notice patient Notice patient italien 04-07-2023
Rapport public d'évaluation Rapport public d'évaluation italien 04-07-2023
Notice patient Notice patient letton 04-07-2023
Rapport public d'évaluation Rapport public d'évaluation letton 04-07-2023
Notice patient Notice patient lituanien 04-07-2023
Rapport public d'évaluation Rapport public d'évaluation lituanien 04-07-2023
Notice patient Notice patient hongrois 04-07-2023
Rapport public d'évaluation Rapport public d'évaluation hongrois 04-07-2023
Notice patient Notice patient maltais 04-07-2023
Rapport public d'évaluation Rapport public d'évaluation maltais 04-07-2023
Notice patient Notice patient néerlandais 04-07-2023
Rapport public d'évaluation Rapport public d'évaluation néerlandais 04-07-2023
Notice patient Notice patient polonais 04-07-2023
Rapport public d'évaluation Rapport public d'évaluation polonais 04-07-2023
Notice patient Notice patient portugais 04-07-2023
Rapport public d'évaluation Rapport public d'évaluation portugais 04-07-2023
Notice patient Notice patient roumain 04-07-2023
Rapport public d'évaluation Rapport public d'évaluation roumain 04-07-2023
Notice patient Notice patient slovaque 04-07-2023
Rapport public d'évaluation Rapport public d'évaluation slovaque 04-07-2023
Notice patient Notice patient slovène 04-07-2023
Rapport public d'évaluation Rapport public d'évaluation slovène 04-07-2023
Notice patient Notice patient finnois 04-07-2023
Rapport public d'évaluation Rapport public d'évaluation finnois 04-07-2023
Notice patient Notice patient suédois 04-07-2023
Rapport public d'évaluation Rapport public d'évaluation suédois 04-07-2023
Notice patient Notice patient norvégien 04-07-2023
Notice patient Notice patient islandais 04-07-2023
Notice patient Notice patient croate 04-07-2023
Rapport public d'évaluation Rapport public d'évaluation croate 04-07-2023

Afficher l'historique des documents